SG11202100076RA - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same - Google Patents
Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the sameInfo
- Publication number
- SG11202100076RA SG11202100076RA SG11202100076RA SG11202100076RA SG11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA
- Authority
- SG
- Singapore
- Prior art keywords
- preventing
- same
- pharmaceutical compositions
- cancers including
- treating cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180086768A KR101954370B1 (en) | 2018-07-25 | 2018-07-25 | Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same |
| PCT/KR2019/001737 WO2020022600A1 (en) | 2018-07-25 | 2019-02-13 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100076RA true SG11202100076RA (en) | 2021-02-25 |
Family
ID=65760263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100076RA SG11202100076RA (en) | 2018-07-25 | 2019-02-13 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11292786B2 (en) |
| EP (1) | EP3810601A4 (en) |
| JP (1) | JP6806931B2 (en) |
| KR (1) | KR101954370B1 (en) |
| CN (2) | CN112469715B (en) |
| AR (1) | AR119657A1 (en) |
| BR (1) | BR112021001122A2 (en) |
| CA (1) | CA3106961A1 (en) |
| CL (1) | CL2021000175A1 (en) |
| DO (1) | DOP2021000017A (en) |
| MX (1) | MX2021000941A (en) |
| PE (1) | PE20210373A1 (en) |
| PH (1) | PH12021550124A1 (en) |
| SG (1) | SG11202100076RA (en) |
| TW (1) | TWI839363B (en) |
| WO (1) | WO2020022600A1 (en) |
| ZA (1) | ZA202100485B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20212153A1 (en) * | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | PHARMACEUTICAL COMPOSITION COMPRISING AN FLT3 INHIBITOR AND A HYPOMETHYLATING AGENT TO TREAT ACUTE MYELOID LEUKEMIA |
| US20220354842A1 (en) * | 2019-06-27 | 2022-11-10 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| WO2021066443A1 (en) * | 2019-09-30 | 2021-04-08 | 한미약품 주식회사 | Pharmaceutical composition for treating acute myeloid leukemia containing flt3 inhibitor and mdm2 inhibitor |
| WO2022098083A1 (en) * | 2020-11-05 | 2022-05-12 | 한미약품 주식회사 | Pharmaceutical composition for treating leukemia comprising flt3 inhibitor |
| BR112023016986A2 (en) * | 2021-02-26 | 2023-11-07 | Tyra Biosciences Inc | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE |
| WO2022216097A1 (en) * | 2021-04-08 | 2022-10-13 | 주식회사 스탠다임 | Novel lrrk2 inhibitor |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| KR20230056331A (en) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | Therapeutically effective combination of a FLT3 inhibitor and a Bcl-2 inhibitor for the treatment of acute myeloid leukemia |
| IL313670A (en) | 2021-12-30 | 2024-08-01 | Biomea Fusion Inc | Pyrazine compounds as inhibitors of flt3 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| EP2212293A4 (en) | 2007-10-24 | 2010-12-01 | Merck Sharp & Dohme | Heterocycle amide t-type calcium channel antagonists |
| FR2926553B1 (en) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | SILANYL SUBSTITUTED INDOLE-2-CARBOXAMIDE AND AZAINDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CA2767089A1 (en) * | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| MY162132A (en) * | 2010-06-23 | 2017-05-31 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| TW201219383A (en) * | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
| WO2014155300A2 (en) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| US10106526B2 (en) * | 2014-04-04 | 2018-10-23 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2018002217A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as nik inhibitors |
| HUE056472T2 (en) * | 2017-01-26 | 2022-02-28 | Hanmi Pharm Ind Co Ltd | Pyrimidine compound and pharmaceutical use thereof |
-
2018
- 2018-07-25 KR KR1020180086768A patent/KR101954370B1/en active IP Right Grant
-
2019
- 2019-02-13 MX MX2021000941A patent/MX2021000941A/en unknown
- 2019-02-13 JP JP2019566602A patent/JP6806931B2/en active Active
- 2019-02-13 EP EP19841611.7A patent/EP3810601A4/en active Pending
- 2019-02-13 CN CN201980049569.8A patent/CN112469715B/en active Active
- 2019-02-13 CN CN202310204523.7A patent/CN116693506A/en active Pending
- 2019-02-13 SG SG11202100076RA patent/SG11202100076RA/en unknown
- 2019-02-13 BR BR112021001122-6A patent/BR112021001122A2/en unknown
- 2019-02-13 PE PE2021000090A patent/PE20210373A1/en unknown
- 2019-02-13 CA CA3106961A patent/CA3106961A1/en active Pending
- 2019-02-13 WO PCT/KR2019/001737 patent/WO2020022600A1/en active Application Filing
- 2019-07-09 TW TW108124118A patent/TWI839363B/en active
- 2019-07-24 AR ARP190102087A patent/AR119657A1/en unknown
-
2020
- 2020-04-27 US US16/859,413 patent/US11292786B2/en active Active
-
2021
- 2021-01-15 PH PH12021550124A patent/PH12021550124A1/en unknown
- 2021-01-22 CL CL2021000175A patent/CL2021000175A1/en unknown
- 2021-01-22 ZA ZA2021/00485A patent/ZA202100485B/en unknown
- 2021-01-22 DO DO2021000017A patent/DOP2021000017A/en unknown
-
2022
- 2022-01-25 US US17/583,841 patent/US20230002358A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3810601A4 (en) | 2022-04-20 |
| ZA202100485B (en) | 2023-11-29 |
| WO2020022600A1 (en) | 2020-01-30 |
| PE20210373A1 (en) | 2021-02-26 |
| CN112469715A (en) | 2021-03-09 |
| PH12021550124A1 (en) | 2021-09-27 |
| KR101954370B1 (en) | 2019-03-05 |
| JP2020527128A (en) | 2020-09-03 |
| US20230002358A1 (en) | 2023-01-05 |
| US20200255410A1 (en) | 2020-08-13 |
| EP3810601A1 (en) | 2021-04-28 |
| JP6806931B2 (en) | 2021-01-06 |
| CA3106961A1 (en) | 2020-01-30 |
| AR119657A1 (en) | 2022-01-05 |
| CL2021000175A1 (en) | 2021-07-02 |
| DOP2021000017A (en) | 2021-04-15 |
| US11292786B2 (en) | 2022-04-05 |
| BR112021001122A2 (en) | 2021-04-13 |
| CN116693506A (en) | 2023-09-05 |
| CN112469715B (en) | 2024-06-11 |
| MX2021000941A (en) | 2021-03-09 |
| TWI839363B (en) | 2024-04-21 |
| TW202014417A (en) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202100076RA (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| EP3533466A4 (en) | Pharmaceutical composition for cancer treatment and/or prevention | |
| IL279347A (en) | Gremlin-1 antagonist for the prevention and treatment of cancer | |
| EP3858353A4 (en) | Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof | |
| IL263793A (en) | Compounds and compositions for the treatment of cancer | |
| EP3847283A4 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| GB201819957D0 (en) | Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same | |
| IL275525A (en) | Pharmaceutical composition for the treatment of cancer | |
| IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
| SG11202007119UA (en) | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | |
| IL279609A (en) | Bifunctional compositions for the treatment of cancer | |
| EP3689355A4 (en) | Pharmaceutical composition for preventing or treating liver cancer | |
| IL284124A (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| EP3290051A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| PL3810128T3 (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
| EP3372233A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| IL282692A (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer | |
| GB202001368D0 (en) | Pharmaceutical composition for preventing or treating cancer containign recepto tyrosine kinase inhibitor as active ingredient | |
| KR102483492B9 (en) | 25- 25-disubstituted pyrimidines and pharmaceutical composition comprising the same | |
| PT3813832T (en) | Compounds for use in preventing or treating cancer | |
| EP3498284A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| IL281782A (en) | Pharmaceutical combination for the treatment of cancer | |
| EP3437655A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP3437656A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP3409281A4 (en) | Pharmaceutical composition for treating and/or preventing cancer |